Previous studies have shown that, although immunotherapy approaches such as targeting immune checkpoint by ICB are beneficial in many cancer entities to promote a proinflammatory TME, EGFR-driven NSCLC tumours do not respond to this type of therapy [9,11,12]. This evidence concerns the gene EGFR and neoplasm.